Breaking News Instant updates and real-time market news.

AGEN

Agenus

$4.35

-0.1 (-2.25%)

, INCY

Incyte

$105.07

-0.1 (-0.10%)

08:53
11/30/16
11/30
08:53
11/30/16
08:53

Agenus begins Phase 1/2 trial of anti-OX40 agonist antibody for solid tumors

Agenus (AGEN) has dosed the first patient in a Phase 1/2 clinical trial of the anti-OX40 agonist antibody INCAGN1949. The trial is being conducted by, and in collaboration with, Incyte (INCY). The open-label, dose-escalation portion of the trial will evaluate the safety and tolerability of INCAGN1949 in patients with advanced or metastatic solid tumors and determine its pharmacologically active and/or maximum tolerated dose. Part 2 of the trial is planned to evaluate the recommended dose of INCAGN1949 in multiple tumor types.

AGEN

Agenus

$4.35

-0.1 (-2.25%)

INCY

Incyte

$105.07

-0.1 (-0.10%)

  • 03

    Dec

  • 04

    Dec

AGEN Agenus
$4.35

-0.1 (-2.25%)

12/16/15
JEFF
12/16/15
INITIATION
Target $8
JEFF
Buy
Agenus initiated with a Buy at Jefferies
Jefferies analyst Biren Amin started Agenus with a Buy rating and $8 price target.
12/16/15
12/16/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Abeona Therapeutics (ABEO) initiated with a Buy at Maxim... Accelerate Diagnostics (AXDX) initiated with an Overweight at Piper Jaffray... Aetna (AET) initiated with a Neutral at Credit Suisse... Agenus (AGEN) initiated with a Buy at Jefferies... Apple Hospitality REIT (APLE) initiated with a Buy at Canaccord... Brunswick (BC) initiated with an Overweight at JPMorgan... Carlisle (CSL) initiated with a Buy at Wunderlich... Castlight Health (CSLT) initiated with a Buy at Topeka... Centene (CNC) initiated with an Outperform at Credit Suisse... ConAgra (CAG) initiated with a Buy at Jefferies... Dean Foods (DF) initiated with a Buy at Jefferies... First Merchants (FRME) initiated with a Neutral at SunTrust... Flowers Foods (FLO) initiated with a Buy at Jefferies... Glatfelter (GLT) initiated with a Buy at Sidoti... HCA Holdings (HCA) initiated with an Outperform at Credit Suisse... Hain Celestial (HAIN) assumed with a Buy at Jefferies... Hormel Foods (HRL) initiated with a Buy at Jefferies... Humana (HUM) initiated with a Neutral at Credit Suisse... Ingredion (INGR) initiated with a Buy at Jefferies... J & J Snack Foods (JJSF) initiated with a Hold at Jefferies... J.M. Smucker (SJM) initiated with a Buy at Jefferies... Kura Oncology (KURA) initiated with a Buy at Citi... LifePoint (LPNT) initiated with an Outperform at Credit Suisse... MasterCard (MA) initiated with a Buy at UBS... Matador (MTDR) initiated with a Neutral at BofA/Merrill... McCormick (MKC) initiated with a Hold at Jefferies... Molina Healthcare (MOH) initiated with a Neutral at Credit Suisse... NetApp (NTAP) initiated with an Underperform at JMP Securities... Nimble Storage (NMBL) initiated with a Market Perform at JMP Securities... Pilgrim's Pride (PPC) initiated with a Hold at Jefferies... Pure Storage (PSTG) initiated with an Outperform at JMP Securities... Rexford Industrial (REXR) initiated with a Buy at Stifel... Rice Energy (RICE) initiated with a Hold at Deutsche Bank... Sanderson Farms (SAFM) initiated with an Underperform at Jefferies... Snyder's-Lance (LNCE) initiated with a Buy at Jefferies... SodaStream (SODA) initiated with a Hold at Jefferies... Tenet (THC) initiated with a Neutral at Credit Suisse... TreeHouse (THS) initiated with a Buy at Jefferies... Tyson Foods (TSN) initiated with a Buy at Jefferies... UnitedHealth (UNH) initiated with an Outperform at Credit Suisse... Universal Health (UHS) initiated with a Neutral at Credit Suisse... Varonis (VRNS) initiated with a Buy at Lake Street... Visa (V) initiated with a Buy at UBS... WellCare (WCG) initiated with an Underperform at Credit Suisse... WhiteWave (WWAV) initiated with a Buy at Jefferies... aTyr Pharma (LIFE) initiated with a Neutral at Citi.
03/11/16
MAXM
03/11/16
UPGRADE
Target $7
MAXM
Buy
Agenus upgraded to Buy from Hold at Maxim
10/28/16
HCWC
10/28/16
DOWNGRADE
Target $5
HCWC
Neutral
Agenus downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth downgraded Agenus to Neutral saying any significant clinical results are at least 12-18 months away. The analyst expects the stock to be range bound given a lack of catalysts. He cut his price target for the shares to $5 from $10.
INCY Incyte
$105.07

-0.1 (-0.10%)

11/17/16
LEER
11/17/16
NO CHANGE
Target $115
LEER
Outperform
Incyte price target raised to $115 from $101 at Leerink
Leerink analyst Michael Schmidt raised his price target for Incyte (INCY) to $115 from $101 after Gilead (GILD) reported disappointing top-line results from two Phase III studies evaluating momelotinib, its JAK1/2 inhibitor for patients with myelofibrosis. The analyst believes that the removal of this uncertainty on the revenue outlook of Incyte's key commercial product, combined with increasing prospects of a repatriation holiday should make the company more attractive as an acquisition target. He reiterates an Outperform rating on Incyte's shares.
11/17/16
BMOC
11/17/16
NO CHANGE
BMOC
Incyte drug won't have 'meaningful competition,' says BMO Capital
BMO Capital analyst M. Ian Somaiya says that "mixed data" on Gilead's (GILD) momelotinib in myelofibrosis eliminates any "meaningful competition" faced by Incyte's (INCY) Jakafi in the disease. The analyst raised his price target on Incyte to $126 from $121 and keeps an Outperform rating on the shares.
11/18/16
RHCO
11/18/16
NO CHANGE
RHCO
Incyte has several positive catalysts, says SunTrust
SunTrust analyst PEter Lawson says he expects Incyte's baricitinib, which he calls a key profitability driver for the company, to be approved by the FDA next quarter. He also expects the company to benefit from positive data on its epacadostat and IOs in solid tumor settings. The analyst keeps a Buy rating on the shares.
11/18/16
GABE
11/18/16
NO CHANGE
Target $99
GABE
Buy
Incyte, Regeneron among Gilead M&A options after latest setback, says Gabelli
Gabelli analyst Jing He noted Gilead's (GILD) "mixed" results from its Phase III trials evaluating momelotinib, which showed that the drug is not superior to Incyte's (INCY) Jakafi. Commenting on Gilead's potential path after momelotinib's "disappointing" results and several other pipeline setbacks this year, He suggested that Gilead could look to buy Incyte, which looks like "Regeneron lite," or simply buy Regeneron (REGN) itself. The analyst said Gilead could alternately target an orphan drug company such as Alexion (ALXN), Vertex (VRTX) or BioMarin (BMRN). She keeps a Buy rating and $99 per share private market value on Gilead shares, as she expects M&A to be a catalyst for the stock.

TODAY'S FREE FLY STORIES

BDX

Becton Dickinson

$178.35

-6.94 (-3.75%)

, BCR

C.R. Bard

$303.81

50.74 (20.05%)

13:12
04/24/17
04/24
13:12
04/24/17
13:12
Upgrade
Becton Dickinson, C.R. Bard rating change  »

Update: Becton Dickinson…

BDX

Becton Dickinson

$178.35

-6.94 (-3.75%)

BCR

C.R. Bard

$303.81

50.74 (20.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

XLP

Consumer Staples Sector SPDR

$55.42

0.42 (0.76%)

13:11
04/24/17
04/24
13:11
04/24/17
13:11
Options
Large spread in SPDR Consumer Staples ETF »

Large spread in SPDR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:10
04/24/17
04/24
13:10
04/24/17
13:10
General news
Fed's Kashkari said bank regulations made ending too-big-to-fail worse »

Fed's Kashkari said…

SHCAY

Sharp

$3.71

0.059 (1.62%)

, HNHPF

Hon Hai Precision

$6.49

0.14 (2.20%)

13:08
04/24/17
04/24
13:08
04/24/17
13:08
Periodicals
Sharp to likely report FY16 net income of ($227M), Nikkei reports »

Sharp (SHCAY) will likely…

SHCAY

Sharp

$3.71

0.059 (1.62%)

HNHPF

Hon Hai Precision

$6.49

0.14 (2.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REED

Reed's

13:06
04/24/17
04/24
13:06
04/24/17
13:06
Earnings
Reed's reports 2016 EPS (36c) vs. (30c) last year »

Reports 2016 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

KO

Coca-Cola

$43.40

0.33 (0.77%)

13:05
04/24/17
04/24
13:05
04/24/17
13:05
Technical Analysis
Coca-Cola technical comments ahead of results »

There is a bullish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 09

    May

REED

Reed's

13:05
04/24/17
04/24
13:05
04/24/17
13:05
Earnings
Reed's sees Q1 revenue $8.3M vs. $10M last year »

Reed's said it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

13:05
04/24/17
04/24
13:05
04/24/17
13:05
General news
FX Action: USD-CAD »

FX Action: USD-CAD topped…

REED

Reed's

13:03
04/24/17
04/24
13:03
04/24/17
13:03
Hot Stocks
Reed's founder and CEO resigns, becomes Chief Innovation Officer »

Reed's announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

REED

Reed's

13:02
04/24/17
04/24
13:02
04/24/17
13:02
Syndicate
Reed's closes $3.4M private placement »

Reed's announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

BDX

Becton Dickinson

$178.36

-6.93 (-3.74%)

13:00
04/24/17
04/24
13:00
04/24/17
13:00
Upgrade
Becton Dickinson rating change  »

Becton Dickinson upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 04

    May

  • 06

    Jun

JNJ

Johnson & Johnson

$122.72

0.96 (0.79%)

, NVS

Novartis

$74.36

0.955 (1.30%)

12:57
04/24/17
04/24
12:57
04/24/17
12:57
Periodicals
J&J, Novartis, Takeda in talks over Hypermarcas takeover, Reuters says »

Johnson & Johnson…

JNJ

Johnson & Johnson

$122.72

0.96 (0.79%)

NVS

Novartis

$74.36

0.955 (1.30%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$24.29

0.215 (0.89%)

HYPMY

Hypermarcas

$9.66

0.44 (4.77%)

BBD

Banco Bradesco

$10.17

0.33 (3.35%)

CS

Credit Suisse

$15.16

0.705 (4.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 06

    Jun

  • 26

    Jun

REED

Reed's

12:56
04/24/17
04/24
12:56
04/24/17
12:56
Hot Stocks
Breaking Hot Stocks news story on Reed's »

Reed's trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

AMZN

Amazon.com

$898.53

-3.53 (-0.39%)

, W

Wayfair

$46.66

0.7 (1.52%)

12:55
04/24/17
04/24
12:55
04/24/17
12:55
Periodicals
Amazon hopes to launch furniture seller program, Furniture Today reports »

In a report highlighted…

AMZN

Amazon.com

$898.53

-3.53 (-0.39%)

W

Wayfair

$46.66

0.7 (1.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 09

    May

  • 16

    May

  • 17

    May

  • 23

    May

MMM

3M

$193.60

2.1 (1.10%)

12:55
04/24/17
04/24
12:55
04/24/17
12:55
Technical Analysis
3M technical notes before earnings news »

The stock has recently…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

  • 31

    May

CAT

Caterpillar

$96.85

2.53 (2.68%)

12:52
04/24/17
04/24
12:52
04/24/17
12:52
Earnings
On The Fly: What to watch in Caterpillar earnings report »

Caterpillar (CAT) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 09

    May

  • 14

    Jun

MU

Micron

$27.32

-0.64 (-2.29%)

12:51
04/24/17
04/24
12:51
04/24/17
12:51
Options
Bullish sentiment in Micron May 5th options ahead of a company event »

Bullish sentiment in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 07

    Jun

AKRX

Akorn

$32.91

-0.09 (-0.27%)

, FSNUY

Fresenius SE

$19.67

-0.16 (-0.81%)

12:50
04/24/17
04/24
12:50
04/24/17
12:50
Periodicals
Akorn close to buyout deal at $33-$35/share, Reuters reports »

Akorn (AKRX) is near a…

AKRX

Akorn

$32.91

-0.09 (-0.27%)

FSNUY

Fresenius SE

$19.67

-0.16 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSU

Kansas City Southern

$89.22

1.23 (1.40%)

12:49
04/24/17
04/24
12:49
04/24/17
12:49
Hot Stocks
Fitch: Mexican regulation could pressure Kansas City Southern »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 09

    May

AKRX

Akorn

$32.91

-0.09 (-0.27%)

, FSNUY

Fresenius SE

$19.67

-0.16 (-0.81%)

12:47
04/24/17
04/24
12:47
04/24/17
12:47
Periodicals
Breaking Periodicals news story on Akorn, Fresenius SE »

Sources: Fresenius could…

AKRX

Akorn

$32.91

-0.09 (-0.27%)

FSNUY

Fresenius SE

$19.67

-0.16 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKRX

Akorn

$32.91

-0.09 (-0.27%)

, FSNUY

Fresenius SE

$19.67

-0.16 (-0.81%)

12:44
04/24/17
04/24
12:44
04/24/17
12:44
Periodicals
Breaking Periodicals news story on Akorn, Fresenius SE »

Fresenius nears deal to…

AKRX

Akorn

$32.91

-0.09 (-0.27%)

FSNUY

Fresenius SE

$19.67

-0.16 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMA

Comerica

$70.71

2 (2.91%)

12:41
04/24/17
04/24
12:41
04/24/17
12:41
Options
Notable call write in Comerica as shares rally »

Notable call write in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

CRHM

CRH Medical

$5.75

-1.6 (-21.77%)

12:40
04/24/17
04/24
12:40
04/24/17
12:40
Recommendations
CRH Medical analyst commentary  »

Cantor discusses recent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

GOOG

Alphabet

$843.19

1.54 (0.18%)

, GOOGL

Alphabet Class A

$858.95

-1.13 (-0.13%)

12:36
04/24/17
04/24
12:36
04/24/17
12:36
Hot Stocks
Google adds TV to 'DoubleClick' ad buying platform »

Google announced in its…

GOOG

Alphabet

$843.19

1.54 (0.18%)

GOOGL

Alphabet Class A

$858.95

-1.13 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 22

    May

ORAN

Orange SA

$15.98

0.935 (6.22%)

, FB

Facebook

$143.68

-0.12 (-0.08%)

12:36
04/24/17
04/24
12:36
04/24/17
12:36
Hot Stocks
Orange partners with Facebook to launch startup accelerator »

Orange is working with…

ORAN

Orange SA

$15.98

0.935 (6.22%)

FB

Facebook

$143.68

-0.12 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.